David Sachs - Immunitybio Principal CFO
| IBRX Stock | USD 4.97 0.07 1.39% |
Insider
David Sachs is Principal CFO of Immunitybio
| Age | 46 |
| Address | 3530 John Hopkins Court, San Diego, CA, United States, 92121 |
| Phone | 844 696 5235 |
| Web | https://immunitybio.com |
David Sachs Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Sachs against Immunitybio stock is an integral part of due diligence when investing in Immunitybio. David Sachs insider activity provides valuable insight into whether Immunitybio is net buyers or sellers over its current business cycle. Note, Immunitybio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Immunitybio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Sachs over three months ago Disposition of 17242 shares by David Sachs of Immunitybio subject to Rule 16b-3 |
Immunitybio Management Efficiency
The company has return on total asset (ROA) of (0.5635) % which means that it has lost $0.5635 on every $100 spent on assets. This is way below average. Immunitybio's management efficiency ratios could be used to measure how well Immunitybio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.04 in 2024, whereas Return On Tangible Assets are likely to drop (1.26) in 2024. At this time, Immunitybio's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 25.7 M in 2024, whereas Total Assets are likely to drop slightly above 288 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ryan Bloomer | Elevation Oncology | N/A | |
| Johanna FriedlNaderer | Vir Biotechnology | 56 | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| Klaus Frueh | Vir Biotechnology | 64 | |
| Robert Blanks | Ardelyx | 64 | |
| CPA CPA | TG Therapeutics | 42 | |
| Abi MD | BioLineRx | 47 | |
| Igor MSc | CureVac NV | 55 | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
| Joseph Ferra | Elevation Oncology | 49 | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Jeff York | Seres Therapeutics | N/A | |
| Eyal MBA | Protalix Biotherapeutics | 48 | |
| Howard Horn | Vir Biotechnology | 46 | |
| Gloria Lin | Krystal Biotech | N/A | |
| CPA MST | Ardelyx | 50 | |
| Lauren MD | PDS Biotechnology Corp | 64 | |
| Raziel Fried | BioLineRx | N/A | |
| Steven Rice | Vir Biotechnology | 64 | |
| Robert Waltermire | Madrigal Pharmaceuticals | 60 | |
| Kimia Keshtbod | Ardelyx | N/A | |
Management Performance
| Return On Asset | -0.56 |
Immunitybio Leadership Team
Elected by the shareholders, the Immunitybio's board of directors comprises two types of representatives: Immunitybio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immunitybio. The board's role is to monitor Immunitybio's management team and ensure that shareholders' interests are well served. Immunitybio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immunitybio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason JD, General Secretary | ||
| Sandeep MD, Chief Officer | ||
| Richard Adcock, CEO President | ||
| Helen Luu, Chief Officer | ||
| Leonard MD, Chief Officer | ||
| Jason Liljestrom, General Secretary | ||
| Barry MD, Chief Director | ||
| Hans MD, Chief Cellular | ||
| FRCS FACS, Executive Officer | ||
| Regan Lauer, Chief Officer | ||
| David Sachs, Principal CFO | ||
| RAC Dilon, Chief Officer | ||
| Sarah Singleton, Chief Advocacy |
Immunitybio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immunitybio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.56 | ||||
| Operating Margin | (13.14) % | ||||
| Current Valuation | 4.12 B | ||||
| Shares Outstanding | 696.83 M | ||||
| Shares Owned By Insiders | 77.00 % | ||||
| Shares Owned By Institutions | 10.11 % | ||||
| Number Of Shares Shorted | 52.05 M | ||||
| Price To Sales | 484.70 X | ||||
| Revenue | 622 K | ||||
| Gross Profit | 240 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.